Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by francois21on Sep 09, 2013 7:17am
319 Views
Post# 21726400

PBI-4050

PBI-4050Like I've previously said, better than pirfenidone, evene better with pirfenidone....
A successful phase I and after, a phase Ib/II could be followed by very interesting moment.
.


- PBI-4050 compares favorably to Pirfenidone, the only approved drug for IPF - PBI-4050 combined with Pirfenidone further reduces fibrosis in lungs - Data provides for regulatory pathway to address an orphan disease - PBI-4050 on track to enter clinical stage

Bullboard Posts